Rani Therapeutics Stock Soars: Major Partnership and Funding Boost Shares to $10 Target

Maxim doubles Rani Therapeutics price target to $10 after $1B+ Chugai partnership validates RaniPill technology. Company secures $60M funding to advance oral drug delivery platform.